These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20170943)

  • 1. Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Yasumoto A; Sakata A; Ohmori T; Madoiwa S; Ono F; Shima M; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2010 Jun; 125(6):533-7. PubMed ID: 20170943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
    Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C
    J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    Snyder RO; Miao C; Meuse L; Tubb J; Donahue BA; Lin HF; Stafford DW; Patel S; Thompson AR; Nichols T; Read MS; Bellinger DA; Brinkhous KM; Kay MA
    Nat Med; 1999 Jan; 5(1):64-70. PubMed ID: 9883841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
    Fabb SA; Dickson JG
    Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.
    Herzog RW; High KA
    Thromb Haemost; 1999 Aug; 82(2):540-6. PubMed ID: 10605748
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunoradiometric assay of factor IX antigen using monoclonal antibody and classification of hemophilia B].
    Yoshioka A; Ohkubo Y; Nishino M; Sakai T; Sugimoto M; Nishimura T; Tanaka I; Fukui H
    Rinsho Ketsueki; 1985 Feb; 26(2):159-65. PubMed ID: 4021109
    [No Abstract]   [Full Text] [Related]  

  • 8. The rhesus macaque as an animal model for hemophilia B gene therapy.
    Lozier JN; Metzger ME; Donahue RE; Morgan RA
    Blood; 1999 Mar; 93(6):1875-81. PubMed ID: 10068660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral vector-mediated gene therapy for hemophilia B.
    Eisensmith RC; Woo SL
    Thromb Haemost; 1997 Jul; 78(1):24-30. PubMed ID: 9198122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor IX: Insights from knock-out and genetically engineered mice.
    Monahan PE
    Thromb Haemost; 2008 Oct; 100(4):563-75. PubMed ID: 18841277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological approaches to the study of the mechanism of hemostasis and thrombosis: applications of monoclonal antibodies against factor IX; a review.
    Kojima T; Takamatsu J; Sano M
    Nihon Ketsueki Gakkai Zasshi; 1987 Dec; 50(8):1697-701. PubMed ID: 3328950
    [No Abstract]   [Full Text] [Related]  

  • 14. Gene therapy for hemophilia: clinical trials and technical tribulations.
    Viiala NO; Larsen SR; Rasko JE
    Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards gene therapy for hemophilia B.
    Anson DS; Hock RA; Austen D; Smith KJ; Brownlee GG; Verma IM; Miller AD
    Mol Biol Med; 1987 Feb; 4(1):11-20. PubMed ID: 3475525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemophilia B with inhibitor].
    Takahashi I
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):502-5. PubMed ID: 9833555
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene therapy of hemophilia B.
    Kurachi K; Yao SN
    Thromb Haemost; 1993 Jul; 70(1):193-7. PubMed ID: 8236102
    [No Abstract]   [Full Text] [Related]  

  • 18. Factor IX gene therapy for hemophilia.
    Fewell JG
    Methods Mol Biol; 2008; 423():375-82. PubMed ID: 18370215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for hemophilia: a step closer to reality.
    White GC; Roberts HR
    Mol Ther; 2000 Mar; 1(3):207-8. PubMed ID: 10933934
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.